FOR IMMEDIATE RELEASE: FULL RNS 27 JANUARY 2015
IMMUPHARMA
Advance Assurance Received from H M Revenue and Customs Regarding
"Enterprise Investment Scheme" Status
ImmuPharma PLC (AIM: IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received advance assurance from H M Revenue and Customs that it would qualify for Enterprise Investment Scheme (EIS) status.
EIS offers a range of tax reliefs to investors who invest in qualifying companies. These tax reliefs would be available provided that the individual and the Company continue to meet the rules of the Scheme at the time of the investment and for a period of 3 years subsequently.
Commenting on the agreement, Richard Warr, ImmuPharma's Executive Chairman, said: "We are pleased to have received this advanced assurance from HM Revenue and Customs. Qualifying for EIS gives ImmuPharma access to the broadest range of potential investors and investment funds."
ENDS
For further information please contact:
|
ImmuPharma plc |
+ 44 (0) 20 7152 4080 |
|
Dimitri Dimitriou, Chief Executive Officer |
|
|
Dr Robert Zimmer, President and Chief Scientific Officer |
|
|
Richard Warr, Chairman Tracy Weimar, Vice President, Operations and Finance |
|
|
Lisa Baderoon, Head of Investor Relations |
+ 44 (0) 7721 413496 |
|
Panmure, Gordon & Co., NOMAD & Broker |
+44 (0) 20 7886 2500 |
|
Hugh Morgan Fred Walsh Duncan Monteith |
|
This information is provided by RNS